NKF advises IHZD through sale transaction
Niederer Kraft Frey (NKF) advised the shareholders of Swiss medical research institute IHZD on its sale to Affidea Group.
The context
IHZD, short for Institut für histologische und zytologische Diagnostik, operates two laboratories in Aarau and Zurich. The institute hosts specialisations in histopathology, molecular pathology and cytology diagnostics.
Amongst Europe’s largest providers of diagnostic imaging, ambulatory care and cancer treatment, Affidea completed the acquisition of IHZD. As a result of the transaction, the buyer further expands its oncological treatment pathway, now integrating prevention, early detection, genetic testing, diagnosis, personalised treatment and post-treatment support.
The team
Corporate/M&A partner Thomas Brönnimann (pictured) led the NKF team on the matter, further supported by associates Manuel Hirlinger and Benedikt Hadorn, junior associate Matthias Zinniker (all corporate/M&A), associate Stephanie Huchler (employment) as well as senior associate Sven Kälin and associate Aleksa Stojadinovic (both tax).
